Impact of eradication of Pseudomonas aeruginosa on survival in Mexican patients with cystic fibrosis

被引:0
作者
Bustamante, Adriana Ester [1 ]
Mercado-Longoria, Roberto [1 ]
Tijerina-Menchaca, Rolando [2 ]
Mas-Trevino, Marcela [2 ]
Torres-Rodriguez, Julian [1 ]
机构
[1] Univ Autonoma Nuevo Leon, Hosp Univ Jose Eleuterio Gonzalez, Clin Fibrosis Quist CEPREP, Serv Neumol, Monterrey 64460, NL, Mexico
[2] Univ Autonoma Nuevo Leon, Fac Med, Dept Microbiol, Ctr Reg Control Enfermedades Infecciosas, Monterrey 64460, NL, Mexico
来源
REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION | 2014年 / 66卷 / 04期
关键词
Cystic fibrosis; Pseudomonas aeruginosa; Eradication; Chronic colonization; Mortality; YOUNG-CHILDREN; CROSS-INFECTION; RISK-FACTORS;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction. Patients with cystic fibrosis (CF) present lower airway infection with Pseudomonas aeruginosa. Treatment of initial infection is fundamental to reduce subsequent damage. Material and methods. We evaluated the efficacy of eradication treatment of P. aeruginosa in patients with CF from northeast Mexico using two protocols: inhaled coils-tin/oral ciprofloxacin and nebulized tobramycin 300 mg/oral ciprofloxacin. The intervention group included 17 patients with CF and recent infection with P. aeruginosa. The control group consisted of 23 chronically colonized patients of comparable age. Results. Patients received 27 courses of eradication treatment. P. aeruginosa was eradicated in 21/27 (77.77%). The infection free period was 16.9 +/- 11.7 months (colistin) and 17 +/- 9.7 months (tobramycin) with no statistically significant difference (P = 0.97). Conclusions. Treated patients maintained normal lung function, better nutritional status, and a better chest X-ray score. In the control group 17/23 (73.9%) patients died with no deaths in the study group.
引用
收藏
页码:307 / 313
页数:7
相关论文
共 32 条
  • [1] ATS/ERS, 2005, ATS ERS TASK FORC ST
  • [2] Long term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis
    Ballmann, M
    Rabsch, P
    von der Hardt, H
    [J]. THORAX, 1998, 53 (09) : 732 - 737
  • [3] Castanos C, 2004, FIBROSIS QUISTICA, P79
  • [4] Cystic Fibrosis Foundation, 2010, PAT REG 2009 ANN DAT
  • [5] Cystic Fibrosis Foundation Evidence based Guidelines for management of infants with cystic fibrosis, 2009, J PEDIAT, V155, pS73
  • [6] Acquisition and eradication of P. aeruginosa in young children with cystic fibrosis
    Douglas, T. A.
    Brennan, S.
    Gard, S.
    Berry, L.
    Gangell, C.
    Stick, S. M.
    Clements, B. S.
    Sly, P. D.
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2009, 33 (02) : 305 - 311
  • [7] Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
    Emerson, J
    Rosenfeld, M
    McNamara, S
    Ramsey, B
    Gibson, RL
    [J]. PEDIATRIC PULMONOLOGY, 2002, 34 (02) : 91 - 100
  • [8] Farrel PM, 2001, AN PEDIAT BARC, V107, P1
  • [9] Association between Mucoid Pseudomonas Infection and Bronchiectasis in Children with Cystic Fibrosis
    Farrell, Philip M.
    Collins, Jannette
    Broderick, Lynn S.
    Rock, Michael J.
    Li, Zhanhai
    Kosorok, Michael R.
    Laxova, Anita
    Gershan, William M.
    Brody, Alan S.
    [J]. RADIOLOGY, 2009, 252 (02) : 534 - 543
  • [10] Fisher JJ, 1999, PEDIATR PULM, VS19, pS265